Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

By sjmartinez • April 21, 2023

Duong VH, Ruppert AS, Mims AS, Borate U, Stein EM, Baer MR, Stock W, Kovacsovics T, Blum W, Arellano ML, Schiller GJ, Olin RL, Foran JM, Litzow MR, Lin TL, Patel PA, Foster MC, Redner RL, Al-Mansour Z, Cogle CR, Swords RT, Collins RH, Vergilio JA, Heerema NA, Rosenberg L, Yocum AO, Marcus S, Chen T, Druggan F, Stefanos M, Gana TJ, Shoben AB, Druker BJ, Burd A, Byrd JC, Levine RL, Boyiadzis MM. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer. 2023 Apr 20. doi: 10.1002/cncr.34780. Epub ahead of print. PMID: 37078412.

Tags: Acute myeloid leukemia, Decitabine, entospletinib, Hematology/Oncology, hypomethylating agents, Publications, tumor protein p53 (TP53)

Depression and Inflammation in Women with Breast Cancer: Risk and Resilience Factors

Korecki JRT, Slavich GM, Ganz PA, Irwin MR, Cole S, Crespi CM, Bower JE. Depression and Inflammation in Women with Breast Cancer: Risk and Resilience[...]

Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate Cancer

Valle LF, Li J, Desai H, Hausler R, Haroldsen C, Chatwal M, Ojo M, Kelley MJ, Rebbeck TR, Rose BS, Rettig MB, Nickols NG, Garraway[...]

Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists

Rugo HS, Bardia A, Gradishar WJ, Hamilton EP, Hurvitz SA, Jhaveri K, Mahtani R, Tolaney SM. Expert consensus on treating HR+/HER2- metastatic breast cancer based[...]